Macrophage colony stimulating factor receptor antagonists - Pipeline Insight, 2024

This “Macrophage colony stimulating factor receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Macrophage colony stimulating factor receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Macrophage colony stimulating factor receptor antagonists Understanding

Macrophage colony stimulating factor receptor antagonists: Overview

Macrophage-colony stimulating factor (CSF-1) signaling through its receptor (CSF-1R) promotes the differentiation of myeloid progenitors into heterogeneous populations of monocytes, macrophages, dendritic cells, and bone-resorbing osteoclasts. In the periphery, CSF-1 regulates the migration, proliferation, function, and survival of macrophages, which function at multiple levels within the innate and adaptive immune systems. Macrophage populations elicited by CSF-1 are associated with, and exacerbate, a broad spectrum of pathologies, including cancer, inflammation, and bone disease. Conversely, macrophages can also contribute to immunosuppression, disease resolution, and tissue repair. Macrophage colony-stimulating factor. Inhibition of macrophage-colony stimulating factor reduces immune cell infiltration and inflammation in the EAE model that mimics the massive invasion of systemic immune cells in the CNS. In the same line, macrophage-colony stimulating factor deficiency prevents tumor invasion in glioblastoma.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Macrophage colony stimulating factor receptor antagonists R&D. The therapies under development are focused on novel approaches for Macrophage colony stimulating factor receptor antagonists.

Macrophage colony stimulating factor receptor antagonists Emerging Drugs Chapters

This segment of the Macrophage colony stimulating factor receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Macrophage colony stimulating factor receptor antagonists Emerging Drugs

Pacritinib: CTI Bio Pharma Pacritinib is an investigational, oral multi-kinase inhibitor with specificity for JAK2, IRAK1, and CSF1R, developed for the treatment of patients with myeloproliferative diseases including myelofibrosis. Unlike other JAK2 inhibitors, pacritinib does not inhibit JAK1. Inhibition of JAK1 has been associated with immune dysfunction and lymphomas, and may also worsen thrombocytopenia and anemia. Pacritinib’s unique MOA, inhibiting JAK2 and IRAK1 without inhibiting JAK1, may allow for reductions of both splenomegaly and constitutional symptoms and may reduce the risk of cytopenias and immune dysfunction associated with other JAK inhibitors. Pacritinib’s New Drug Application (NDA) is under priority review with the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of November 30,2021.

AMB 051: AmMax Bio Licensed from Amgen, AMB-05X is a human monoclonal antibody against the CSF1R (M-CSF-R, c-fms). Delivered intra-articularly via a patented technology and with a clinically validated target, AMB-05X represents a best-in-class and well-differentiated therapeutic option with minimal side effects that would potentially address the significant unmet needs for the entire spectrum of TGCTpatients.

Macrophage colony stimulating factor receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Macrophage colony stimulating factor receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Macrophage colony stimulating factor receptor antagonists

There are approx. 18+ key companies which are developing the Macrophage colony stimulating factor receptor antagonists. The companies which have their Macrophage colony stimulating factor receptor antagonists drug candidates in the most advanced stage, i.e. Preregistration include, CTI BioPharma.

Phases

This report covers around 18+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Macrophage colony stimulating factor receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Macrophage colony stimulating factor receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Macrophage colony stimulating factor receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Macrophage colony stimulating factor receptor antagonists drugs.

Macrophage colony stimulating factor receptor antagonists Report Insights

• Macrophage colony stimulating factor receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Macrophage colony stimulating factor receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Macrophage colony stimulating factor receptor antagonists drugs?
• How many Macrophage colony stimulating factor receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Macrophage colony stimulating factor receptor antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Macrophage colony stimulating factor receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Macrophage colony stimulating factor receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CTI BioPharma
• AmMax Bio
• Novartis
• Plexxikon
• Daiichi Sankyo Company
• Basilea Pharmaceutica
• Turning Point Therapeutics
• HUTCMED
• Elixiron Immunotherapeutics
• BCI Pharma
• Signal ChemLifesciences
• Eli Lilly and Company
• Nerviano Medical Sciences
• Roche
• Qurient Co
• Chipscreen Biosciences
• Abbisko Therapeutics
• Janssen Research & Development
• Bristol-Myers Squibb
• Syndax Pharmaceuticals

Key Products

• Pacritinib
• AMB 051
• BLZ 945
• Cabiralizumab
• PLX-3397
• Quizartinib
• Axatilimab
• PLX4720
• Edicotinib
• ABSK 021
• Chiauranib
• Derazantinib
• NMS 03592088
• Q 702
• Emactuzumab
• Elzovantinib
• Surufatinib
• EI 003
• EI 1071
• BCI 1415
• IMC CS4

This product will be delivered within 2-4 business days.